Sign inCreate account

Report workspace tools

NCT06465186ACTIVE_NOT_RECRUITINGanonymous

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Sponsor

Source record

Merck Sharp & Dohme LLC

Phase

Source record

Phase 2a

Modality

AI-normalized

combination therapy

Target

AI-normalized

Efinopegdutide (MK-6024) targets metabolic dysfunction-associated steatohepatitis (MASH) by potentially reducing liver fat, inflammation, and fibrosis.

Indication / condition

AI-normalized

Non-alcoholic Fatty Liver Disease

Intervention

Source record

Efinopegdutide, Placebo

Source & freshness

Source record

NCT ID

NCT06465186

Original source

ClinicalTrials.gov

Source last updated

Mar 02, 2026

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06465186

Title

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Sponsor

Merck Sharp & Dohme LLC

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2a

Condition raw

Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis

Condition normalized

Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis

Modality raw

combination therapy

Modality normalized

combination therapy

Target raw

Efinopegdutide (MK-6024) targets metabolic dysfunction-associated steatohepatitis (MASH) by potentially reducing liver fat, inflammation, and fibrosis.

Target normalized

Efinopegdutide (MK-6024) targets metabolic dysfunction-associated steatohepatitis (MASH) by potentially reducing liver fat, inflammation, and fibrosis.

Interventions

Efinopegdutide, Placebo

Public preview

Source record

Efinopegdutide is being developed by Merck Sharp & Dohme LLC for the treatment of compensated cirrhosis secondary to MASH, a condition with significant unmet medical need and increasing prevalence due to rising obesity and diabetes rates. The global market for therapies targeting liver diseases, particularly NASH/MASH, is projected to grow substantially, with numerous competitors also in development. Successful outcomes from this trial could position Merck favorably in a competitive landscape, potentially leading to a first-in-class designation if efinopegdutide demonstrates superior efficacy and safety. Diligence should focus on the regulatory pathway, potential market access challenges, and the evolving competitive landscape as other candidates progress through clinical trials.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06465186

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2a

Sponsor

Merck Sharp & Dohme LLC

Executive brief

Investment-Ready Snapshot

Efinopegdutide is being developed by Merck Sharp & Dohme LLC for the treatment of compensated cirrhosis secondary to MASH, a condition with significant unmet medical need and increasing prevalence due to rising obesity and diabetes rates. The global market for therapies targeting liver diseases, particularly NASH/MASH, is projected to grow substantially, with numerous competitors also in development. Successful outcomes from this trial could position Merck favorably in a competitive landscape, potentially leading to a first-in-class designation if efinopegdutide demonstrates superior efficacy and safety. Diligence should focus on the regulatory pathway, potential market access challenges, and the evolving competitive landscape as other candidates progress through clinical trials.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 02, 2026
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06465186

Indication

Non-alcoholic Fatty Liver Disease

Modality

combination therapy

Target

Efinopegdutide (MK-6024) targets metabolic dysfunction-associated steatohepatitis (MASH) by potentially reducing liver fat, inflammation, and fibrosis.

Intervention

Efinopegdutide, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.